Carregant...
Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement
BACKGROUND: Olmesartan medoxomil (OLM), an anti-hypertensive agent administered orally has absolute bioavailability of only 26% due to the poor aqueous solubility (<7.75 μg/ml). The present investigation aimed at enhancing the oral bioavailability of OLM by improving its solubility and dissolutio...
Guardat en:
Autors principals: | , , |
---|---|
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
Medknow Publications Pvt Ltd
2011
|
Matèries: | |
Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3178951/ https://ncbi.nlm.nih.gov/pubmed/21966165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0975-7406.84459 |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|